Zogenix (ZGNX) Announces FDA Extension of Review Period for FINTEPLA in Dravet Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. BLZE
7. IBM
8. NKE
9. MU
10. ACN

Go back to Zogenix (ZGNX) Announces FDA Extension of Review Period for FINTEPLA in Dravet Syndrome
ZOGENIX (NASDAQ: ZGNX) Delayed: 26.68 --0 (-0%)
Previous Close $26.68    52 Week High $16.56 
Open $0.25    52 Week Low $7.33 
Day High $26.68    P/E N/A 
Day Low $26.68    EPS $-0.40 
Volume 65,263,395